| Trial ID: | L3123 |
| Source ID: | NCT01288326
|
| Associated Drug: |
Liraglutide
|
| Title: |
Observational Study on Effectiveness and Safety of Liraglutide in Subjects With Type 2 Diabetes
|
| Acronym: |
ROOTS
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes|Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: liraglutide
|
| Outcome Measures: |
Primary: Percentage of participants with a decrease in HbA1c (glycosylated haemoglobin A1c) of at least 1%, month 12|Percentage of participants reaching the treatment target of a HbA1c (glycosylated haemoglobin A1c) decrease of at least 1%, month 12 | Secondary: HbA1c, month 12|Fasting blood glucose (FBG), month 12|Incidence of serious adverse events (SAEs), months 0-12|Incidence of adverse drug reactions (ADRs), months 0-12|Frequency of hypoglycaemic episodes (frequency of episodes with low blood sugar), months 0-12
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
254
|
| Study Type: |
OBSERVATIONAL
|
| Study Designs: |
Observational Model: |Time Perspective: p
|
| Start Date: |
2011-02
|
| Completion Date: |
2013-03
|
| Results First Posted: |
|
| Last Update Posted: |
2017-01-26
|
| Locations: |
Novo Nordisk Investigational Site, Brussels, 1070, Belgium
|
| URL: |
https://clinicaltrials.gov/show/NCT01288326
|
